We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+19.88%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.1B
AUM Growth
+$208M
Cap. Flow
+$144M
Cap. Flow %
13.12%
Top 10 Hldgs %
54.38%
Holding
136
New
36
Increased
27
Reduced
26
Closed
32

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$35.5M
2
NVO
Novo Nordisk
NVO
+$19.7M
3
URGN icon
UroGen Pharma
URGN
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$12.4M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$10.9M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$19.7M
2
CELG
Celgene Corp
CELG
+$18.8M
3
ITRN icon
Ituran Location and Control
ITRN
+$14.6M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$11.6M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 55.27%
2 Technology 6.57%
3 Consumer Discretionary 1.18%
4 Industrials 1.08%
5 Communication Services 0.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$302M 27.56%
3,335,000
+635,000
+24% +$54M
BMY icon
2
Bristol-Myers Squibb
BMY
$133B
$42M 3.83%
879,900
+249,900
+40% +$12.4M
JNJ icon
3
Johnson & Johnson
JNJ
$618B
$37M 3.38%
+265,000
New +$35.5M
FOLD
4
DELISTED
Amicus Therapeutics
FOLD
$33.8M 3.09%
2,488,078
+40,084
+2% +$490K
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$33.4M 3.05%
247,300
+79,200
+47% +$9.85M
MRK icon
6
Merck
MRK
$322B
$31.4M 2.86%
395,096
-99,560
-20% -$7.45M
GILD icon
7
Gilead Sciences
GILD
$162B
$31.2M 2.85%
480,000
+130,000
+37% +$8.64M
VTRS icon
8
Viatris
VTRS
$20.4B
$28.4M 2.59%
1,002,307
-674,934
-40% -$19.7M
CELG
9
PUT
DELISTED
Celgene Corp
CELG
$28.3M 2.58%
+300,000
New +$26.2M
AZN icon
10
AstraZeneca
AZN
$263B
$28.3M 2.58%
350,000
+92,500
+36% +$7.29M
CELG
11
DELISTED
Celgene Corp
CELG
$23.6M 2.15%
250,000
-215,000
-46% -$18.8M
NVO
12
Novo Nordisk
NVO
$208B
$20.9M 1.91%
+800,000
New +$19.7M
GSK icon
13
GSK
GSK
$104B
$18M 1.64%
344,000
+96,000
+39% +$4.8M
VRNT
14
DELISTED
Verint Systems
VRNT
$15.8M 1.44%
518,087
+225,404
+77% +$5.73M
BIIB icon
15
PUT
Biogen
BIIB
$30B
$14.2M 1.29%
+60,000
New +$18.9M
BLUE
16
DELISTED
bluebird bio
BLUE
$13.2M 1.2%
6,469
-4,246
-40% -$7.48M
QURE icon
17
CALL
uniQure
QURE
$3.03B
$11.9M 1.09%
+200,000
New +$8.93M
URGN icon
18
UroGen Pharma
URGN
$1.86B
$11.4M 1.04%
+308,377
New +$12.9M
ICPT
19
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$11.2M 1.02%
+100,000
New +$10.9M
TVTX icon
20
Travere Therapeutics
TVTX
$5.2B
$9.86M 0.9%
435,678
+110,000
+34% +$2.43M
ALDX icon
21
Aldeyra Therapeutics
ALDX
$92.9M
$9.65M 0.88%
1,069,089
-163,000
-13% -$1.39M
NVS icon
22
Novartis
NVS
$297B
$9.61M 0.88%
+111,600
New +$8.96M
SRPT icon
23
Sarepta Therapeutics
SRPT
$1.57B
$8.75M 0.8%
73,405
-43,112
-37% -$5.54M
PTCT icon
24
PTC Therapeutics
PTCT
$5.68B
$8.3M 0.76%
220,500
-125,000
-36% -$4.2M
CLLS
25
Cellectis
CLLS
$277M
$8.22M 0.75%
447,970
– –
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2019 Portfolio in Review

As of Q1 2019, Sphera Funds Management held 136 positions worth $1.1B, up 23% from $887M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sphera Funds Management deployed $144M of net new capital in Q1 2019, opening 36 new positions and adding to 27 existing holdings. Its largest new stake was Johnson & Johnson: 265,000 shares worth $37M.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 60% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Viatris, an estimated $19.7M trimmed.

  • Sphera Funds Management's largest Q1 2019 buy was Johnson & Johnson: 265,000 shares worth $37M.
  • Sphera Funds Management added most to Bristol-Myers Squibb in Q1 2019, an estimated $12.4M increase.
  • Sphera Funds Management's biggest Q1 2019 reduction was Viatris, cutting an estimated $19.7M.
  • Sphera Funds Management fully exited Ituran Location and Control in Q1 2019, selling an estimated $14.6M.
  • Sphera Funds Management's ten largest holdings make up 54% of its $1.1B portfolio in Q1 2019.
  • Sphera Funds Management opened 36 new positions and closed 32 in Q1 2019.
  • Sphera Funds Management's portfolio value rose 23% quarter-over-quarter to $1.1B.

Based on Sphera Funds Management's 13F filing for Q1 2019, filed 15 May 2019.